Persistent corneal epithelial defect responding to rebamipide ophthalmic solution in a patient with diabetes
Authors:
Open Access
- 1 May 2016
- journal article
- Published by Taylor & Francis in International Medical Case Reports Journal
- Vol. ume 9, 113-116
Abstract
Objective: Rebamipide ophthalmic suspension was developed for the treatment of dry eyes and for other corneal diseases, promoting the secretion of both mucin in tear fluid and membrane-associated mucin, increasing the number of goblet cells, and restoring the barrier function of the corneal epithelium. We report a case of a persistent corneal epithelial defect in a patient with diabetes treated with topical application of rebamipide ophthalmic suspension. Case presentation: A 73-year-old woman had a history of type 2 diabetes for 35 years and nonproliferative diabetic retinopathy for 23 years. She presented to our department with discharge and ophthalmalgia in the left eye. A corneal ulcer was detected, and culture of corneal scrapings was performed, with Staphylococcus aureus and Streptococcus canis being isolated. The infection was treated with levofloxacin eye drops and ofloxacin ophthalmic ointment based on the sensitivity profile of the isolate. However, a corneal epithelial defect persisted for approximately 2 months despite continuing treatment with 0.1% hyaluronic acid ophthalmic suspension and 0.3% ofloxacin eye ointment. Her hemoglobin A1c was 7.3%. The persistent corneal epithelial defect showed improvement at 2 weeks after treatment with rebamipide unit dose 2% ophthalmic suspension, and it did not recur even when vitrectomy was subsequently performed for vitreous hemorrhage due to progression of diabetic retinopathy. Conclusion: This is the first report about efficacy of rebamipide unit dose 2% ophthalmic suspension for presenting persistent corneal epithelial defect in a patient with diabetes. In the present case, the suggested mechanisms are the following: improving the corneal barrier function, stabilization of mucin on the keratoconjunctival epithelium, and improving the wettability and stability of the tear film, which resulted in the promotion of healing of the corneal epithelial defect in a short time period.Keywords
This publication has 27 references indexed in Scilit:
- Ocular surface disease in patients with diabetic peripheral neuropathyBritish Journal of Ophthalmology, 2015
- Novel Therapy to Treat Corneal Epithelial Defects: A Hypothesis with Growth HormoneThe Ocular Surface, 2015
- Effect of Rebamipide Ophthalmic Suspension on Signs and Symptoms of Keratoconjunctivitis Sicca in Sjögren Syndrome Patients With or Without Punctal OcclusionsCornea, 2014
- Topical Rebamipide Treatment for Superior Limbic Keratoconjunctivitis in Patients With Thyroid Eye DiseaseAmerican Journal of Ophthalmology, 2014
- Topical rebamipide improves lid wiper epitheliopathyClinical Ophthalmology, 2013
- Topical rebamipide improves the ocular surface in mild lagophthalmosClinical Ophthalmology, 2013
- Involvement of advanced glycation end products, oxidative stress and nuclear factor-kappaB in the development of diabetic keratopathyGraefe's Archive for Clinical and Experimental Ophthalmology, 2010
- Ocular manifestations of diabetes mellitusCurrent Opinion in Ophthalmology, 1999
- Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in ratsDigestive Diseases and Sciences, 1993
- Studies on 2(1H)-quinolinone derivatives as gastric antiulcer active agents. 2-(4-Chlorobenzoylamino)-3-(2(1H)-quinolinon-4-yl)propionic acid and related compounds.Chemical and Pharmaceutical Bulletin, 1985